ACADIA Pharmaceuticals (ACAD) Stock

We have just released a list of 10 companies that are expected to finish 2024 on a strong note with significant gains. In this article, we will examine how ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) compares to these other firms. The last trading day of the year saw a lack of excitement on Wall Street.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As described at the time the agreement to sell was announced on November 5, 2024, Acadia is required to pay Neuren Pharmaceuticals Limited one-third of the net proceeds, pursuant to a license agreement between the companies. Acadia plans to invest proceeds from the sale of the PRV to.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the bo.

ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, Acadia.com under the investors section and will be archived.